Abivax prices 10.2M ADSs at $64.00 in underwritten public offering

Abivax (ABVX) announces the pricing of its previously announced underwritten public offering of 10,156,000 American Depositary Shares, each representing one ordinary share, EUR 0.01 nominal value per share, of the Company, in the United States at an offering price of $64.00 per ADS. The offering price of $64.00 per ADS is equal to the volume weighted average price of the Ordinary Shares on the regulated market of Euronext in Paris over the last 3 trading sessions preceding the pricing of the Offering, plus a premium of 21.0% and has been determined by the CEO upon subdelegation from the Board of Directors pursuant to the 22nd resolution of the Company’s combined shareholders’ meeting held on June 6, 2025. Leerink Partners, Piper Sandler & Co. and Guggenheim Securities are acting as joint bookrunning managers for the Offering. LifeSci Capital is acting as lead manager, with BTIG and Van Lanschot Kempen acting as co-managers for the Offering. The Offering is expected to close on July 28, 2025, subject to the satisfaction of customary closing conditions.